Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Breast Neoplasms 9Ovarian Neoplasms 1Neoplasm Metastasis 1Fallopian Tube Neoplasms 1Estrogen Receptor Positive 1Endometrial Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1Brain Neoplasms 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Temozolomide 17Bevacizumab 10Radiotherapy 9Carmustine 9Magnetic Resonance Spectroscopy 7Erlotinib Hydrochloride 7Carboplatin 7Sorafenib 6Lapatinib 6Chemotherapy, Adjuvant 62,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 6temsirolimus 5Vorinostat 5Surgical Procedures, Operative 5Sirolimus 5Radiosurgery 5Radiation 5Dexamethasone 5cediranib 4Immunoglobulin G 4Disulfides 4Cyclophosphamide 4Cilengitide 4pazopanib 3Thalidomide 3Procarbazine 3Nivolumab 3Neoadjuvant Therapy 3Irinotecan 3Iodine-125 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Brain Neoplasms × Fulvestrant × Clear all
NCT03803761 2023-09-25

A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
BreastCNS

Brain Neoplasms, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡